Welcome to our dedicated page for Alexandria Real Estate Eq news (Ticker: ARE), a resource for investors and traders seeking the latest updates and insights on Alexandria Real Estate Eq stock.
Alexandria Real Estate Equities, Inc. reports news as a life science real estate investment trust that owns, operates and develops collaborative Megacampus™ ecosystems in major life science innovation clusters. Company updates commonly cover operating results, funds from operations, leasing activity, rental-rate trends and property-market demand across locations such as Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle and New York City.
Recurring announcements also include quarterly common stock dividends, balance-sheet and liquidity commentary, capital recycling activity, senior note offerings, cash tender offers for outstanding debt and corporate governance or leadership matters tied to the REIT’s public-company structure.
Alexandria Real Estate Equities (NYSE: ARE) will hold a conference call and live audio webcast on Tuesday, October 27, 2026, at 2:00 p.m. ET to discuss its third quarter 2026 operating and financial results, which will be released after market close on Monday, October 26, 2026.
Investors can join via phone in the U.S./Canada at (833) 366-1125 or internationally at (412) 902-6738, or listen through the webcast at http://investor.are.com/webcasts. A replay will be available from 4:00 p.m. ET on October 27 through 4:00 p.m. ET on November 3, 2026 using replay lines and access code 6457127.
Alexandria Real Estate Equities (NYSE: ARE) priced a public offering of $1,000,000,000 aggregate principal amount of 7.250% Series A fixed-to-fixed reset rate junior subordinated notes due 2057, at 100.000% of principal.
The notes will bear interest at 7.250% per year until February 15, 2032, then reset every five years to the five-year U.S. Treasury Rate plus 2.889%, with a 7.250% floor. They are junior subordinated unsecured obligations of the company, fully and unconditionally guaranteed on a subordinated unsecured basis by Alexandria Real Estate Equities, L.P. Closing is expected on or about August 21, 2026, subject to customary conditions. The company intends to use net proceeds for general corporate purposes, including potential debt reduction and property-related investments.
Alexandria Real Estate Equities (NYSE: ARE) reported 2Q26 net loss attributable to common stockholders of $(73.7) million, or $(0.43) per diluted share, and 1H26 net income of $286.7 million, or $1.68 per diluted share. 2Q26 FFO per share – diluted, as adjusted, was $1.73 (1H26: $3.46), versus $2.33 and $4.63 in the prior-year periods.
Operating occupancy was 86.9%, or 90.9% including executed leases with future occupancy, with 2Q26 leasing volume of 1,038,917 RSF, up 60% from 1Q26. Same-property NOI declined 10.6% (8.6% cash) in 2Q26, driven by previously disclosed large lease expirations. According to Alexandria, liquidity totaled $3.60 billion, net debt and preferred to Adjusted EBITDA was 7.0x (2Q26 annualized), and only 6% of total debt matures through 2028.
Alexandria Real Estate Equities (NYSE: ARE) announced a key milestone in its mission-critical partnership with the Foundation for the National Institutes of Health (FNIH): the Multi-Modal Assessment and Phenotyping in Depression (MAP-D) initiative has completed its critical design phase for a first-of-its-kind precision medicine clinical study in major depressive disorder.
Launched with Alexandria’s initial vision and funding, and its role as FNIH’s founding strategic partner, MAP-D aims to identify and validate biological signatures of depression to enable more personalized treatment and support development of more effective therapies. According to Alexandria, the long-term research effort is expected to exceed $70 million, beginning with a $22 million, three-year pilot phase. The study plans to use advanced AI models, generate one of the most comprehensive depression datasets to date, define biologically informed subtypes of depression, and make data broadly accessible to qualified researchers to accelerate scientific discovery in depression and other serious mental illnesses.
Alexandria Real Estate Equities (NYSE: ARE) announced the delivery of a 427,000 rentable square feet (RSF) state-of-the-art research and development hub for Bristol Myers Squibb at the Campus Point by Alexandria Megacampus in San Diego. BMS becomes an anchor tenant, extending a strategic relationship with Alexandria dating back to 1998.
As of March 31, 2026, Campus Point was 95.4% occupied and totaled 2.9 million RSF, comprising 1.3 million RSF of operating properties, 0.9 million RSF under construction and 0.7 million RSF for future development and redevelopment. In the San Diego region, Alexandria reported 6.2 million RSF of operating assets and 0.9 million RSF of development assets, reinforcing its cluster-focused Megacampus strategy built around proximity to leading institutions such as Salk Institute, Scripps Research and the University of California, San Diego.
Alexandria Real Estate Equities (NYSE: ARE) reaffirmed its longstanding partnership with the National Medal of Honor Museum Foundation as the U.S. approaches its 250th anniversary. The company highlights support for preserving stories of Medal of Honor Recipients and advancing leadership and educational initiatives.
According to Alexandria, executive chairman and founder Joel S. Marcus has served on the Foundation’s board since 2020. The National Medal of Honor Museum in Arlington, Texas, opened in March 2025, spans 100,000 square feet and was named USA Today Reader’s Choice 2026 “Best New Museum.”
Alexandria Real Estate Equities (NYSE: ARE) released its 2025 Corporate Responsibility Report, showcasing the integration of mission, innovation and long-term value creation across its Megacampus platform.
Highlights include multiple trust and philanthropy awards, STEM and biomedical partnerships, GRESB Green Star status, and a 16% reduction in operational GHG emissions intensity since 2022 with 32% renewable electricity in 2025.
Alexandria Real Estate Equities (NYSE: ARE) was ranked 16th in talent readiness among all S&P 500 companies in The Wall Street Journal's inaugural "Best Companies for the Future" list and was the highest-ranked equity REIT in this category.
The recognition highlights Alexandria's people-first culture, long-tenured leadership averaging 15 years, strong internal advancement, comprehensive development programs and a benefits package that includes 100% company-paid medical premiums and the Alexandria Lifeline™ specialized-care offering.
Alexandria Real Estate Equities (NYSE: ARE) highlights its long-term role building New York City's commercial life science ecosystem and investing in early-stage biotech through Alexandria Venture Investments.
The firm is cited as the second most active institutional life science investor in NYC and showcases exits including Petra Pharmaceuticals' 2020 sale to Eli Lilly and Intra-Cellular Therapies' $14.6 billion acquisition by Johnson & Johnson in 2025.
Alexandria Real Estate Equities (NYSE: ARE) declared a quarterly cash dividend of $0.72 per common share for 2Q26. The dividend is payable on July 15, 2026 to shareholders of record on June 30, 2026.
The $0.72 dividend matches the prior quarter, implying a 5.8% yield based on the May 28, 2026 close and a 42% dividend payout ratio for the three months ended March 31, 2026.